aTyr Pharma, Inc. (NASDAQ:LIFE – Get Free Report) was the recipient of a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 231,400 shares, an increase of 5.5% from the October 15th total of 219,400 shares. Based on an average trading volume of 180,700 shares, the short-interest ratio is currently 1.3 days.
Analyst Upgrades and Downgrades
LIFE has been the topic of several research analyst reports. Piper Sandler boosted their price target on aTyr Pharma from $13.00 to $20.00 and gave the company an “overweight” rating in a research note on Thursday, July 20th. StockNews.com lowered shares of aTyr Pharma from a “hold” rating to a “sell” rating in a research report on Monday. Finally, HC Wainwright restated a “buy” rating and set a $35.00 price objective on shares of aTyr Pharma in a research note on Thursday, September 21st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $20.75.
Institutional Trading of aTyr Pharma
aTyr Pharma Stock Performance
NASDAQ:LIFE traded up $0.02 during trading hours on Friday, reaching $1.16. The company had a trading volume of 127,647 shares, compared to its average volume of 362,121. The firm has a market cap of $67.93 million, a PE ratio of -1.18 and a beta of 1.22. aTyr Pharma has a 1-year low of $1.08 and a 1-year high of $2.70. The business’s 50 day moving average price is $1.40 and its 200-day moving average price is $1.86. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.33 and a quick ratio of 8.33.
aTyr Pharma Company Profile
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.
- Five stocks we like better than aTyr Pharma
- What is the Nikkei 225 index?
- 3 large caps with red hot RSIs with upside
- How and Why to Invest in Oil Stocks
- Johnson Controls International: Nothing but upside for investors
- What is the Shanghai Stock Exchange Composite Index?
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.